CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Continuous Glucose Monitor (CGM)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04756141
NCT04756141N/ACompleted
CompareCT.gov

Continuous Glucose Monitor (CGM) Use in COVID-19 Patients

Mayo Clinic·interventional·Posted Feb 16, 2021·Updated Aug 4, 2023

In Brief

A clinical study evaluating Continuous Glucose Monitor (CGM) for Diabetes Mellitus and Covid19. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as point of care (POC) glucose monitors. Also if found to be accurate, CGM reading data will be used together with POC glucometers to dose insulin therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Covid19
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 16, 2021
Enrollment StartMar 3, 2021
Primary CompletionAug 24, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.4 years ago

Interventions

Continuous Glucose Monitor (CGM)device

A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.